Loading organizations...

§ Private Profile · Morrisville, NC, USA
Animal health diagnostics company developing rapid on-farm tests for livestock producers, focused on early disease detection.
Based in Morrisville, North Carolina, Advanced Animal Diagnostics develops rapid, on-farm diagnostic testing systems that allow livestock producers to detect diseases early and manage antibiotic use. The company's primary hardware technology, the QScout Farm Lab, analyzes animal blood and milk at the cellular level to identify conditions such as subclinical mastitis in dairy cows and bovine respiratory disease in beef cattle. Operating with an estimated workforce of 11 to 50 employees, the enterprise has secured $52.44 million in total venture capital funding, including a $15 million Series C financing round. The agricultural technology firm is backed by prominent institutional investors such as Cultivian Sandbox Ventures, Novartis Venture Funds, and Intersouth Partners. The corporate board has also featured notable industry executives including former Neogen Corporation chief executive officer James Herbert. Advanced Animal Diagnostics was founded in 2001 by Rudy Rodriguez.
Advanced Animal Diagnostics has raised $43.6M across 6 funding rounds.
Advanced Animal Diagnostics has raised $43.6M in total across 6 funding rounds.
Advanced Animal Diagnostics has raised $43.6M in total across 6 funding rounds.
Advanced Animal Diagnostics's investors include Mountain Group Partners, Cultivian Sandbox Ventures, Kansas Bioscience Authority, Middleland Capital, Intersouth Partners, Labcorp, Novartis, James Rosen, Simon Wheeler.
Advanced Animal Diagnostics (AAD) is a technology company founded in 2001 that develops rapid, on-farm diagnostic tools for the livestock sector, enabling producers to detect diseases like subclinical mastitis and bovine leukosis early.[1][3] Its flagship products, such as the QScout® MLD for dairy cattle mastitis detection and QScout® BLD for beef producers, provide point-of-care testing to inform real-time management decisions, reduce antibiotic use, boost animal productivity, and support global protein demand.[1][2][3] Serving livestock and agriculture industries, AAD has raised $52.44M, holds 20 patents in immunology and zoonoses, and remains in the Grant - II stage as an active company headquartered in Morrisville, North Carolina.[1]
The company solves critical challenges in animal health by delivering actionable, onsite data that prevents losses, improves profitability, and enhances food safety without relying on slow lab tests.[1][3] This positions AAD at the intersection of agtech and diagnostics, with growth evidenced by expanded offerings, board leadership driving diversification (e.g., sister company Ad Astra Diagnostics for human applications), and ongoing engineering advancements like the SCC+ system.[1][2]
Advanced Animal Diagnostics was established in 2001 in Morrisville, North Carolina, initially focusing on point-of-care testing for cow-side diagnostics in livestock.[1] Key details on founders are not specified in available sources, but the company's evolution accelerated under board chairman Jeffrey Shapiro, who joined in 2014 following his venture firm's investment and assumed leadership in 2015.[1] A pivotal moment came with the development of the QScout platform, including early prototypes for subclinical mastitis detection (SCC+ system), which proved novel technology's potential despite initial limitations.[2][3]
Early traction built through iterative engineering partnerships, such as with Porticos, which refined mechanical layouts, incorporated new functionality, and provided tooling for fully working prototypes to demonstrate value to agriculture industries.[2] This groundwork expanded AAD into beef diagnostics (QScout BLD) and human diagnostics via Ad Astra, marking a shift from niche animal testing to broader precision health applications.[1][3]
AAD rides the agtech precision farming wave, where IoT-enabled diagnostics address rising global protein demand amid labor shortages, antibiotic resistance, and supply chain pressures.[1][3] Timing aligns with post-2020 emphases on food security and sustainability, as on-farm tools reduce vet dependency and lab delays in an industry facing disease outbreaks like mastitis, which costs dairy billions annually.[3] Market forces favoring AAD include regulatory pushes for reduced antibiotics and investor interest in agtech (evidenced by $52M raised), positioning it to influence ecosystem-wide shifts toward data-driven livestock management.[1]
By enabling proactive health decisions, AAD contributes to broader trends in animal welfare, sustainable agriculture, and even human diagnostics crossover, amplifying startup innovation in rural tech stacks.[1][2]
AAD's momentum—fueled by patent strength, product iterations, and funding—points to scaled adoption in dairy and beef sectors, potentially expanding QScout to more diseases or international markets.[1][2][3] Trends like AI-enhanced diagnostics, climate-resilient farming, and one-health initiatives (linking animal/human health) will shape its path, with Ad Astra signaling human market entry.[1] Influence may evolve from niche livestock player to agtech diagnostics leader, driving ecosystem profitability and sustainability; watch for Series funding or acquisitions to accelerate this. This builds on AAD's core promise: empowering producers with information that counts for healthier animals and thriving agriculture.[3]
Advanced Animal Diagnostics has raised $43.6M across 6 funding rounds. Most recently, it raised $7.0M Series E in May 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| May 1, 2021 | $7M Series E | — | Mountain Group Partners | Announced |
| Jan 21, 2018 | $3M Debt Financing | — | — | Announced |
| Mar 10, 2016 | $1.7M Venture Round | — | Cultivian Sandbox Ventures, Kansas Bioscience Authority, Middleland Capital | Announced |
| Dec 9, 2014 | $15M Series C | Cultivian Sandbox Ventures, Kansas Bioscience Authority | Intersouth Partners, Labcorp, Middleland Capital, Novartis | Announced |
| Apr 10, 2013 | $6M Series B | — | Intersouth Partners, Novartis | Announced |
| Mar 15, 2011 | $11M Series B | James Rosen | Simon Wheeler | Announced |